McQueen Ball & Associates Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 0.6% during the second quarter, Holdings Channel reports. The institutional investor owned 58,397 shares of the biopharmaceutical company’s stock after buying an additional 360 shares during the period. Pfizer accounts for about 1.5% of McQueen Ball & Associates Inc.’s holdings, making the stock its 19th largest position. McQueen Ball & Associates Inc.’s holdings in Pfizer were worth $2,056,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Bloom Tree Partners LLC purchased a new position in shares of Pfizer during the first quarter worth approximately $35,682,000. State of Alaska Department of Revenue raised its position in shares of Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock worth $13,093,000 after buying an additional 37,647 shares in the last quarter. BlackRock Group LTD raised its position in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares in the last quarter. Charter Trust Co. raised its position in shares of Pfizer by 4.3% in the second quarter. Charter Trust Co. now owns 377,918 shares of the biopharmaceutical company’s stock worth $13,306,000 after buying an additional 15,510 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 0.31% during midday trading on Friday, hitting $32.66. 15,569,339 shares of the stock were exchanged. The company has a 50 day moving average price of $34.02 and a 200 day moving average price of $34.27. The firm has a market capitalization of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the company posted $0.56 EPS. Equities analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
PFE has been the topic of a number of recent analyst reports. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Jefferies Group dropped their target price on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, September 13th. Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 target price on shares of Pfizer in a research report on Monday, August 22nd. Finally, Argus reissued a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research report on Tuesday, October 4th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.